Asimov has announced a cell line development partnership with Kaigene to support the development of next-generation antibody therapeutics for pathogenic antibody-mediated autoimmune diseases. The collaboration covers the complete cell line development process, from vector design and synthesis to the production and shipment of a high-titer research cell bank for Kaigene’s multispecific antibody candidate. Kaigene’s platform is designed to selectively degrade pathogenic antibodies associated with autoimmune diseases, addressing the longer-term treatment options beyond conventional approaches such as steroids, immunosuppressants, and antibody therapies. Asimov will use its AI-driven vector design platform to evaluate molecule-specific vector configurations and conduct the campaign through its CHO Edge System, which combines a proprietary GS knock-out CHO host, hyperactive transposase, genetic parts library, and Kernel AI-driven genetic design software.
Also Read: Gamma Technologies and Gotion Illinois Partner to Accelerate Battery Development
“We need new approaches to provide long term treatment of challenging autoimmune diseases, and Kaigene’s antibody degrader technology has the potential to advance the field considerably,” said Alec Nielsen, co-founder and CEO at Asimov. “We are proud to support Kaigene as they advance their novel multispecific for the millions of patients globally in need of better care.” “Kaigene has created a leading pipeline of innovative antibody therapeutics, and we are committed to working with best-in-class partners to accelerate our team’s progress,” said Minjae Shin, Chief Executive Officer at Kaigene. “We are excited to partner with the experts at Asimov, and leverage their AI-driven CHO Edge System to create a high-performance cell line and accelerate our progress toward the clinic.”
